Results 31 to 40 of about 34,696 (251)
Pharmaceuticals, 2023 When developing novel radiopharmaceuticals, a linker moiety between the chelator and targeting vector can have a crucial influence on adjusting the affinity of the tracer and its biodistribution in organisms.
Qing Ruan +6 more
doaj +1 more source
Radiopharmaceutical Therapy [PDF]
Health Physics, 2019 Abstract Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, peptides, and small molecules) or that concentrate in tumors through natural physiological mechanisms that occur predominantly in neoplastic cells.
openaire +2 more sources
Development of new copper-64 labeled rhodamine: a potential PET myocardial perfusion imaging agent
EJNMMI Radiopharmacy and Chemistry, 2022 Background Myocardial perfusion imaging (MPI) is one of the most commonly performed investigations in nuclear medicine procedures. Due to the longer half-life of the emerging positron emitter copper-64 and its availability from low energy cyclotron ...
Norah AlHokbany +5 more
doaj +1 more source
Clustering Algorithm Reveals Dopamine‐Motor Mismatch in Cognitively Preserved Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To explore the relationship between dopaminergic denervation and motor impairment in two de novo Parkinson's disease (PD) cohorts. Methods n = 249 PD patients from Parkinson's Progression Markers Initiative (PPMI) and n = 84 from an external clinical cohort.
Rachele Malito +14 more
wiley +1 more source
Angewandte Chemie, EarlyView.This work presents the first enzymatic polymerization of defined metal‐chelator‐modified nucleotides that leverage polymerase fidelity for uniform (radio)metal loading with successful incorporation of five different metals: Ga, In, Tb, Lu, and Y.
Antonio A. W. L. Wong +2 more
wiley +2 more sources
Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi +19 more
wiley +1 more source
Chelator‐Free Radiometal Labeling Inside Engineered Affibodies
Angewandte Chemie, EarlyView.Affibodies are compact and robust three‑helix binders used in imaging and therapy. Engineering a triple‑cysteine motif into their core enables chelator‑free binding of important radiometals, like Bi(III), Pb(II), In(III), and Ga(III) with rapid uptake and exceptional stability.
Lani J. Davies +6 more
wiley +2 more sources
Bioinorganic Chemistry and Applications, 2009 A neutral compound Re(CO)3(L) (L: 2-((2-(2,6-diethylphenylamino)-2-oxoethyl)(2-ethoxy-2-oxoethyl)amino)acetic acid, an IDA analogue) has been synthesized and evaluated for in vitro imaging probes of β-amyloid (Aβ) aggregates.
Yang Yang +3 more
doaj +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate Radiopharmaceuticals
PharmaceuticalsBone metastasis is among the most common complications of advanced malignant tumors and severely affects prognosis in patients. Nuclear medicine, particularly bone-targeted radiopharmaceuticals, plays a unique and pivotal role in the diagnosis and ...
Yu Qian +4 more
doaj +1 more source